Amgen sign at its headquarters in Thousand Oaks, California. (Credit: JHVEPhoto/Adobe Stock) Who Got the Work: Saul Ewing Team Appears for Samsung Bioepis in Amgen Patent Case
California-based Amgen has filed a patent infringement suit to stop Samsung Bioepis from developing bone-treatment drugs that would rival two of its top-performing products.
August 22, 2024 at 07:15 PM
4 minute read
Litigation
What You Need to Know
- Samsung Bioepis has applied for approval to develop biosimilar products.
- Amgen contends that the defendants' application is incomplete.
- The biosimilar products would rival Amgen's Prolia and XGEVA products.
A team from Saul Ewing has appeared on behalf of Samsung Bioepis, which faces a patent infringement complaint from Amgen over development of biologic drugs similar to two of the biopharmaceutical giant's top-performing products.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2How I Made Office Managing Partner: 'If You Are Aware of Areas for Improvement and You Can Play a Role in That, Speak Up,' Says Jennifer Mellott of Freshfields
- 3Burns & Levinson to Wind Down After 64 Years in Boston
- 4'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
- 5Will Jones Day Now Prioritize Settlement Talks in Dad Bias Case?
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
